CMND-100 Phase I/IIa Trial Shows Successful Ongoing Treatment, No Serious Adverse Events for Alcohol Use Disorder
CMND is trading near its 52-week low of $0.595 (14% above the low) on elevated volume (2.1× avg).
Summary
Clearmind Medicine reported successful ongoing treatment of participants in the third cohort of its FDA-approved CMND-100 Phase I/IIa clinical trial for Alcohol Use Disorder at US sites. This positive update, following the March 11 announcement of recruitment advancement, highlights continued safety and tolerability with no serious adverse events reported to date. For a micro-cap clinical-stage biotech, positive progress and safety data in an ongoing trial are significant, providing confidence in the drug candidate's development. Investors will monitor future updates on trial completion and efficacy readouts.
At the time of this announcement, CMND was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.59 to $52.40. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.